<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04926051</url>
  </required_header>
  <id_info>
    <org_study_id>MB008-009</org_study_id>
    <nct_id>NCT04926051</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption</brief_title>
  <official_title>A Phase 1, Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose, and a Japanese Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986172, Including an Open-Label Assessment of Relative Bioavailability and Food Effect on the Single-Dose Pharmacokinetics of BMS-986172 in Healthy and Obese Otherwise Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and drug levels of&#xD;
      BMS-986172 and evaluate the effects of food on BMS-986172 absorption.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">May 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of non-serious Adverse Events (AEs)</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation of study treatment</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in physical examination</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Hematology tests</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Chemistry tests</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Urinalysis tests</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Serology tests</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in ECG parameters: QTcF</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of BMS-986172</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T))</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Part A: SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAD = Single Ascending Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD = Multiple Ascending Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: JMAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JMAD= Japanese Multiple Ascending Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: FE/BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FE/BA = Food Effect/Relative Bioavailability</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986172</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part A: SAD</arm_group_label>
    <arm_group_label>Part B: MAD</arm_group_label>
    <arm_group_label>Part C: JMAD</arm_group_label>
    <arm_group_label>Part D: FE/BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part A: SAD</arm_group_label>
    <arm_group_label>Part B: MAD</arm_group_label>
    <arm_group_label>Part C: JMAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit: www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy participants as determined by no clinically significant deviation from normal&#xD;
             in medical history, physical examination, vital signs, ECG, and clinical laboratory&#xD;
             results as determined by the investigator or designee.&#xD;
&#xD;
          -  Participants in Part C must be first-generation Japanese participants. For the purpose&#xD;
             of this study, first-generation Japanese is defined as native Japanese or&#xD;
             first-generation Japanese living outside of Japan for &lt;10 years.&#xD;
&#xD;
          -  BMI of ≥ 18 kg/m2 to ≤ 40.0 kg/m2, inclusive, at screening, except for high BMI cohort&#xD;
             participants (Part B) which will be restricted to a BMI range of ≥ 30 kg/m2 to ≤ 40.0&#xD;
             kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to tolerate the oral lipid meal or the testing conditions on Day -1,&#xD;
             including but not limited to: bloating, nausea, vomiting, diarrhea, pain, or any&#xD;
             discomfort due to oral lipid meal.&#xD;
&#xD;
          -  Any significant acute or chronic medical condition that presents a potential risk to&#xD;
             the participant and/or that may compromise the objectives of the study, including&#xD;
             active, or history of, liver disease, or intestinal disorder including irritable bowel&#xD;
             syndrome.&#xD;
&#xD;
          -  History or presence of malignancy including hematological malignancies; participants&#xD;
             with a history of basal cell or squamous cell carcinoma that has been treated with no&#xD;
             evidence of recurrence within 5 years will be allowed for inclusion, as judged by the&#xD;
             investigator or designee.&#xD;
&#xD;
          -  Any significant acute or chronic medical illness.&#xD;
&#xD;
          -  History of SARS-CoV-2 infection (either suspected or confirmed) within 3 months prior&#xD;
             to signing consent&#xD;
&#xD;
          -  Participants who have received a SARS-CoV-2 vaccine approved for Emergency Use&#xD;
             Authorization by the US FDA that is not live attenuated may be considered for&#xD;
             enrollment&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Participants</keyword>
  <keyword>BMS-986172</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

